DISC MEDICINE INC. - COMMON STOCK

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

19 Oct 2026 16:01:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Success on All Primary and Secondary Endpoints in the Pivotal Phase 3 APOLLO Trial of Bitopertin in Adults and Adolescents with Erythropoietic Protoporphyria (EPP)

19 Oct 2026 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine to Host Corporate Webcast to Discuss Topline Results from the APOLLO Phase 3 Trial of Bitopertin in Erythropoietic Protoporphyria (EPP)

18 Oct 2026 17:00:00 By Nasdaq GlobeNewswire

Disc Medicine Presents Initial Results from RESTORE-PV Phase 2 Trial in Patients with Polycythemia Vera (PV) at the 14th Society of Hematologic Oncology (SOHO) Annual Meeting

09 Sep 2026 19:25:00 By Nasdaq GlobeNewswire

Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer

12 Jan 2026 16:30:00 By Nasdaq GlobeNewswire

Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026

12 Jan 2026 08:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Present at the 44th Annual J.P. Morgan Healthcare Conference

07 Jan 2026 08:30:00 By Nasdaq GlobeNewswire

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

06 Dec 2025 08:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Third Quarter 2025 Financial Results and Provides Business Update

06 Nov 2025 08:30:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

03 Nov 2025 09:00:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

31 Oct 2025 08:30:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

21 Oct 2025 00:14:08 By Nasdaq GlobeNewswire

Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

20 Oct 2025 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Provides Update on Hematology Portfolio and Outlines Near-Term Business Objectives and Anticipated Milestones

20 Oct 2025 06:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Present Data from Phase 1b Trial of DISC-0974 in Patients with Chronic Kidney Disease (CKD) and Anemia at 2025 American Society of Nephrology (ASN) Kidney Week

17 Oct 2025 09:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Receipt of FDA Commissioner’s National Priority Voucher (CNPV) for Bitopertin in Erythropoietic Protoporphyria (EPP)

16 Oct 2025 17:35:18 By Nasdaq GlobeNewswire

Disc Medicine Announces Submission of New Drug Application (NDA) to US FDA for Accelerated Approval of Bitopertin for Patients with Erythropoietic Protoporphyria (EPP)

30 Sep 2025 08:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

27 Aug 2025 08:30:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update

07 Aug 2025 08:30:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Positive Pre-NDA Meeting and Confirms Plans to Submit NDA for Bitopertin in Erythropoietic Protoporphyria (EPP) in October 2025

21 Jul 2025 08:00:00 By Nasdaq GlobeNewswire